Cadavedo, Ian Rose .
HRN: 14-28-34 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/20/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
09/20/2022
09/23/2022
IV
500mg
Q8 For 3 Days
S/P CS MSAF
Waiting Final Action
Indication: ProphylaxisEmpiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes